![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: VEGFD |
Gene summary for VEGFD |
![]() |
Gene information | Species | Human | Gene symbol | VEGFD | Gene ID | 2277 |
Gene name | vascular endothelial growth factor D | |
Gene Alias | FIGF | |
Cytomap | Xp22.2 | |
Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | O43915 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2277 | VEGFD | S014 | Human | Liver | HCC | 2.66e-13 | 5.74e-01 | 0.2254 |
2277 | VEGFD | S015 | Human | Liver | HCC | 6.11e-04 | 3.20e-01 | 0.2375 |
2277 | VEGFD | S016 | Human | Liver | HCC | 1.18e-15 | 5.08e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000166612 | Liver | HCC | response to hypoxia | 172/7958 | 307/18723 | 1.06e-06 | 1.59e-05 | 172 |
GO:003629312 | Liver | HCC | response to decreased oxygen levels | 179/7958 | 322/18723 | 1.29e-06 | 1.87e-05 | 179 |
GO:007048212 | Liver | HCC | response to oxygen levels | 191/7958 | 347/18723 | 1.42e-06 | 2.03e-05 | 191 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0451041 | Liver | HCC | Focal adhesion | 125/4020 | 203/8465 | 3.12e-05 | 1.88e-04 | 1.04e-04 | 125 |
hsa0451051 | Liver | HCC | Focal adhesion | 125/4020 | 203/8465 | 3.12e-05 | 1.88e-04 | 1.04e-04 | 125 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
VEGFD | KDR | VEGFD_VEGFR2 | VEGF | Breast | ADJ |
VEGFD | KDR | VEGFD_VEGFR2 | VEGF | Breast | Healthy |
VEGFD | FLT4 | VEGFD_VEGFR3 | VEGF | Lung | MIAC |
VEGFD | KDR | VEGFD_VEGFR2 | VEGF | Lung | MIAC |
VEGFD | FLT4_KDR | VEGFD_VEGFR2R3 | VEGF | Lung | MIAC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VEGFD | SNV | Missense_Mutation | c.1040G>A | p.Gly347Glu | p.G347E | O43915 | protein_coding | deleterious_low_confidence(0.03) | benign(0.028) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
VEGFD | SNV | Missense_Mutation | c.928N>C | p.Asp310His | p.D310H | O43915 | protein_coding | deleterious(0.01) | possibly_damaging(0.557) | TCGA-21-5782-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
VEGFD | SNV | Missense_Mutation | novel | c.624N>T | p.Gln208His | p.Q208H | O43915 | protein_coding | tolerated(0.2) | benign(0.033) | TCGA-43-A475-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
VEGFD | SNV | Missense_Mutation | rs780418465 | c.751C>T | p.His251Tyr | p.H251Y | O43915 | protein_coding | tolerated(0.36) | benign(0) | TCGA-85-8052-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
VEGFD | SNV | Missense_Mutation | novel | c.98N>G | p.Ser33Cys | p.S33C | O43915 | protein_coding | deleterious(0.01) | benign(0.43) | TCGA-D6-A6EM-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
VEGFD | SNV | Missense_Mutation | c.521N>T | p.Ser174Leu | p.S174L | O43915 | protein_coding | deleterious(0.02) | benign(0.269) | TCGA-VP-A876-01 | Prostate | prostate adenocarcinoma | Male | <65 | 8 | Unknown | Unknown | SD | |
VEGFD | SNV | Missense_Mutation | c.13N>A | p.Trp5Arg | p.W5R | O43915 | protein_coding | deleterious(0) | possibly_damaging(0.641) | TCGA-BR-8380-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | polyplatillen | PD | |
VEGFD | SNV | Missense_Mutation | c.129G>T | p.Gln43His | p.Q43H | O43915 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-BR-8686-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
VEGFD | SNV | Missense_Mutation | c.920T>C | p.Phe307Ser | p.F307S | O43915 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BR-A452-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |